|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
ROC analysis revealed an optimal cut-off point at 7.27 ng/ml HTATIP2/TIP30 for separating the HCC from the control groups.
|
28599422 |
2017 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Here, we show that TIP30, also called CC3, regulates p53 mRNA stability and induces apoptosis by sensing of intracellular oxidative stress in human hepatocellular carcinoma (HCC) cells.
|
18519672 |
2008 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Aspirin did not inhibit the proliferation of HCC cells, but it decreased the invasiveness of HCC with lower expression of HTATIP2 and increased expression of a set of markers, indicating a mesenchymal-to-epithelial transition in tumor cells.
|
23741443 |
2013 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thioredoxin, a prometastasis factor, is negatively regulated by TIP30 and plays an essential role during the process of HCC metastasis.
|
26752068 |
2016 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
To further explore the correlation between TIP30 and HBV infection in HCC, HBV(+) hepatoblastoma cell-line HepG2 2.2.15 and HCC cell-line Hep3B were used.
|
27418384 |
2016 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
CONCLUSIONS MTF can enhance the potential of RGF and inhibit the recurrence and metastasis of HCC after postoperative liver section by regulating the levels of TIP30 and HIF-2α.
|
29654226 |
2018 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Taken together, our data indicate that somatic mutations in the TIP30 gene may abolish its native tumor-suppressor activity and gain oncogenic activities partially through up-regulation of N-cadherin, thereby potentiating the pathogenesis of HCC in patients.
|
17440068 |
2007 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest a novel and critical role of TIP30 involved in HCC progression and aggressiveness.
|
24681951 |
2015 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, immunohistochemical analysis indicates that reduced TIP30 expression is associated with 33% of human hepatocellular carcinomas.
|
14695192 |
2003 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ad-TIP30 carrying exogenous TIP30-anti-tumor genes may be regarded as a potential candidate for the treatment of hepatocellular carcinoma.
|
15633220 |
2005 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Tip30-induced apoptosis requires translocation of Bax and involves mitochondrial release of cytochrome c and Smac/DIABLO in hepatocellular carcinoma cells.
|
17997990 |
2008 |
|
Liver carcinoma
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
Moreover, analyses of Tip30 promoter methylation status in 59 paired HCC tissues showed that 47% of the cases were hypermethylated.
|
19010857 |
2008 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, expression of TIP30 was inversely associated with OPN expression in HCC tissue samples as detected by immunohistochemistry assay.
|
18537194 |
2008 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
To explore the effects of interventional therapy on human immunodeficiency virus (HIV)-1 Tat interactive protein 2/Tat interactive protein 30 (HTATIP2/TIP30), B7-H4 and short-term curative effect in primary hepatocellular carcinoma.
|
30402840 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, TIP30(-/-) mice spontaneously develop hepatocellular carcinoma and other tumors at a higher incidence than that of wild-type mice.
|
26629947 |
2014 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Clinically, our data revealed that TIP30 expression significantly correlated with SREBP1 in patients with HCC and that a combination of TIP30 and SREBP1 is a powerful predictor of HCC prognosis.
|
28604762 |
2017 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we show that TIP30, also called CC3, regulates p53 mRNA stability and induces apoptosis by sensing of intracellular oxidative stress in human hepatocellular carcinoma (HCC) cells.
|
18519672 |
2008 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of TIP30 might be a promising candidate as a treatment for HCC that would increase sensitivity to chemotherapeutic drugs.
|
16799960 |
2006 |
|
Liver carcinoma
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Overexpression of TIP30 might be a promising candidate as a treatment for HCC that would increase sensitivity to chemotherapeutic drugs.
|
16799960 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The loss of function of Tat-interacting protein 30 (TIP30) has been linked to metastasis in non-small cell lung cancer (NSCLC).
|
30099830 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In addition, the decrease in TIP30 protein was correlated with worse overall and progression-free survival of the NSCLC patients.
|
30642057 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Recent studies have identified that decreased expression of TIP30 (30kDa HIV-1 Tat interacting protein) is associated with the metastasis of human NSCLCs, but a causative relationship between TIP30 deficiency and NSCLC development remains unclear.
|
22733137 |
2013 |
|
Non-Small Cell Lung Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Low TIP30 expression levels were found in all 9 cases of small cell lung cancer and in 36.5% (72/197) of non-small cell lung cancer, which were correlated with lymph node metastasis in non-small cell lung cancer and with poor differentiation and advanced stage of tumor cells in squamous cell carcinoma.
|
19349353 |
2009 |
|
Secondary malignant neoplasm of lymph node
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Moreover, decreased TIP30 expression was associated with lymph node metastasis (p < 0.05) and loss of E-cadherin expression (r = 0.329, p < 0.01).
|
24037692 |
2014 |